Skip to main content

Our Impact

With the launch of GBM AGILE, a new path has been uncovered—one that accelerates this pace of discovery from bench to bedside, and offers the greatest hope in the fight against cancer. Many important milestones have already been achieved, but there’s so much more on the horizon. Take a look and see how the generous support of our donors is making a difference, one dollar at a time.

"NFCR helps us focus where focus is needed most. They convene the discussions we must be having, guiding the discoverers who are exploring uncharted ground. NFCR is the navigator."

- Ronald DePinho, M.D., former President of MD Anderson Cancer Center

Ron DePinho

Our Progress

Milestones We’ve Achieved Together


60 Trial Sites in the United States


2,300+ Patients  Screened


50+ Global Sites Selected


7 Pharmaceutical Partners

In addition to the progress already achieved, the AGILE trial design is making an even greater impact. The AGILE trial approach is being used to combat other rare and deadly diseases.